Waregem (Belgium) / Rotterdam (The Netherlands)*, 1 February 2010 – Pursuant to the Belgian legislation of 2 May 2007 relating to the disclosure of major shareholdings in listed companies, Arseus received notification on 28 January that KBC Asset Management NV’s holding had fallen below the disclosure threshold of 3%.
Based on the denominator of 31,195,121 (total number of voting rights) and the relevant notifications, the structure of the shareholding of Arseus is as follows:
Number of shares
Percentage of total
Enhold NV
7,830,000
25.10%
Couckinvest NV/Coucke
3,528,080
11.31%
Fortis Investment Management SA
2,756,357
8.84%
Arseus NV (treasury shares)
973,915
3.12%
Public
16,106,769
51.63%
The original notification forms are also available on the corporate website (www.arseus.com).
More information:
Constantijn van Rietschoten, Investor Relations Manager
+31 88 33 11 222 (office)
+31 6 536 91 585 (mobile)
constantijn.van.rietschoten@arseus.com
Profile Arseus
Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the European healthcare sector. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions. In 2009 Arseus realised turnover of approximately €391 million with 1,600 employees in 16 European countries. The Belgian company Arseus NV is located in Waregem, and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
* This press release was sent out by Arseus NV and Arseus BV.
Please open the link below for the press release: